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CORRESPONDENCE 1467
The G1456 to T Mutation in the Thrombomodulin Gene Is Not Frequent in Patients With Venous Thrombosis
To the Editor: CAGC-3* and 5*-TGGACGGAGCCAGGCTCCTG-3*) were used
to produce two PCR products with overlapping sequences at the
mutagenized end. After the first round of PCR, 1 mL of 1:100 dilutionThrombomodulin is a major component of the protein C anticoag-
ulant pathway.1 Biochemical detection of thrombomodulin defects of the PCR products were used to amplify, in a second round of
PCR, a 153-bp fragment using the TM 23 and TM 24B primers.are hampered by its location in the endothelial cell. The characteriza-
tion of molecular alterations in the thrombomodulin gene of selected The Rsa I digestion pattern of the mutagenized PCR products showed
the introduction of a G to T substitution at nucleotide 1456. Solublepatient populations represents an alternative diagnostic approach.
Recently, a point mutation G1456 to T in the thrombomodulin gene thrombomodulin levels were also measured in patients and controls
by enzyme-linked immunosorbent assay (Asserachrom Thrombo-of a 45-year-old man with venous thrombosis and that of his son
was detected.2 The mutation predicts an Asp468 to Tyr amino acid modulin; Diagnostica Stago, Asnie`re, France), because the reported
patient with the mutation had soluble thrombomodulin levels lesssubstitution and creates a novel restriction site for Rsa I digestion
in the gene. To assess the frequency of this mutation in patients with than the normal laboratory range.2
We could not find the G1456 to T mutation in any of the patientsvenous thrombosis, we screened 100 Italian patients consecutively
referred to the Thrombosis Center for a documented episode of and controls; two of the patients and four control individuals had
soluble thrombomodulin levels less than the normal laboratory rangevenous thrombosis and 100 age- and sex-matched asymptomatic
controls. The most frequent thrombotic episode was deep vein (mean 0 2 SD calculated from 100 determinations in healthy sub-
jects; 7 ng/mL). We conclude that the G1456 to T thrombomodulinthrombosis of the lower limbs (54%), followed by superficial throm-
bophlebitis (21%), pulmonary embolism (14%), cerebral vein throm- gene mutation is not frequently associated with venous thrombosis
in Italy and that it does not account for a significant proportion ofbosis (7%), and visceral vein thrombosis (4%). Characteristics of
the patients are shown in Table 1. the thrombotic episodes that remain still unexplained by the known
causes of hereditary thrombophilia.3 The low levels of soluble throm-The G1456 to T mutation was searched for by amplification and
restriction analysis. Oligonucleotide primers employed were as origi- bomodulin antigen found in two patients and four control individuals
may be due to acquired causes such as an increased turnover or tonally described by Ohlin and Marlar,2 ie, 5*-CGGTACCTTCGA-
GTGCATCT-3* (TM 23) and 5*-ACGGCCGGAGGAGTCAAGGT- a different and as yet unidentified genetic defect in the thrombo-
modulin gene.3* (TM 24B). The original polymerase chain reaction (PCR) method
was used with minor modifications (50 mL reaction mixture, with
annealing at 657C). In addition, a DNA fragment containing the Elena M. Faioni
G1456 to T mutation was constructed as a positive control. Briefly, Giuliana Merati
two sets of oligonucleotides carrying the mutation of interest (5*- Flora Peyvandi
CAGGTGCCAGATGTTTTGCA-3* and 5*-TGTCGCCACCGT- Paola M. Bettini
ACACCTTGCCGGA-3*; 5*-CGGCAAGGTGTACGGTGGCGA- Pier Mannuccio Mannucci
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center
IRCCS Maggiore Hospital and Institute of Internal Medicine
University of MilanoTable 1. Characteristics of 100 Patients With Venous Thrombosis
Milan, Italy
Median age (range) of patients* 44 (17-73)
Sex (Males/Females) 40/60 REFERENCES
Median age (range) at first thrombotic episode 35 (12-65) 1. Esmon CT: The roles of protein C and thrombomodulin in the
Patients with 1 thrombotic episode* (%) 54
regulation of blood coagulation. J Biol Chem 264:4743, 1989
Patients with 2 thrombotic episodes* (%) 26 2. Ohlin A-K, Marlar RA: The first mutation identified in the
Patients with 3 or more thrombotic episodes* (%) 20 thrombomodulin gene in a 45-year-old man presenting with throm-
Median (range) soluble thrombomodulin (ng/mL) boembolic disease. Blood 85:330, 1995
Patients 16 (5-62) 3. De Stefano V, Finazzi G, Mannucci PM: Inherited thrombophi-
Controls 16 (3-47) lia: Pathogenesis, clinical syndromes and management. Blood
87:3531, 1996* At time of referral.
AID Blood 0045 / 5h2e$$1021 01-15-97 20:06:09 bldas WBS: Blood
 For personal use only. by guest on October 18, 2012. bloodjournal.hematologylibrary.orgFrom 
